[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Zagolski O, Dwivedi RC, Subramanian S, Kazi R: Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther; 2010 Jan-Mar;6(1):5-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sino-nasal tract in children.
  • Of all head and neck cancers occurring in children, non-Hodgkin's lymphoma (NHL) is the most common, others being rhabdomyosarcoma and nasopharyngeal carcinoma.
  • In the head and neck region, sinuses are the second commonest primary site of NHL after neck lymph nodes.
  • These can be of several different types depending on the predominant cell type and histologic appearance, the most common histological variant being diffuse large B-cell lymphoma.
  • In an attempt to simplify the classification and to develop a universally acceptable classification and staging, they have been classified and staged numerous times over the last three decades, adding more confusion to the topic.
  • Clinical presentations vary according to the histological type.
  • The low grade lymphomas present with a nasal cavity or para-nasal sinus mass associated with obstructive symptoms and/or lymphadenopathy, while high grade lymphomas present with aggressive signs and symptoms including non-healing ulcer, epistaxis, septal perforation and bony destruction.
  • The primary treatment consists of chemotherapy and / or radiation therapy, which is able to achieve remission in two-third of the patients, however, prognosis remains poor with cumulative five-year survival rates at about 30% for all the types of sino-nasal NHLs.
  • Newer targeted therapy (monoclonal antibodies) and combination therapies (including stem cells) are currently being tested in order to improve survival rates in these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology. Paranasal Sinus Diseases / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Staging. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479539.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


2. Dare AO, Datta RV, Loree TR, Hicks WL, Grand W: Sinonasal Non-Hodgkin's Lymphoma with Skull Base Involvement. Skull Base; 2001 May;11(2):129-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal Non-Hodgkin's Lymphoma with Skull Base Involvement.
  • Non-Hodgkin's lymphoma (NHL) is a rare tumor of the skull base.
  • As the incidence of primary central nervous system (CNS) lymphoma has increased, atypical presentations involving the skull or cranial base exclusively have been reported.
  • In immunocompetent patients with no previous history or predisposing factors, the diagnosis of primary NHL of the skull base may be delayed.
  • We present four cases of nasal and paranasal sinus NHL with both skull base and intracranial involvement in immunocompetent patients.
  • Clinicopathologic correlation suggests that cranial base and intracranial involvement with NHL represents advanced-stage primary sinonasal disease.
  • Surgical biopsy before definitive treatment is recommended.
  • Radiation therapy provides local control; adjuvant chemotherapy after primary radiation therapy may be required for recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol. 1981 Mar;7(1):23-31 [7214760.001]
  • [Cites] J Laryngol Otol. 1995 Aug;109(8):751-4 [7561500.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17(4):567-71 [8331227.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Sep;31B(5):299-300 [8704645.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):395-9 [9031122.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):303-11 [9327155.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):613-5; discussion 615-6 [9733317.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4655-60 [9891536.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] No Shinkei Geka. 1992 Jun;20(6):717-21 [1603282.001]
  • [Cites] Jpn J Clin Oncol. 1992 Apr;22(2):131-5 [1619780.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):723-43 [2190267.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] J Comput Assist Tomogr. 1986 Nov-Dec;10(6):1003-5 [3465759.001]
  • [Cites] AJR Am J Roentgenol. 1987 Oct;149(4):785-91 [3498332.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jun;112(6):654-8 [3516178.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Laryngoscope. 1983 Oct;93(10):1276-80 [6621224.001]
  • [Cites] Med J Aust. 1983 Oct 29;2(9):451-2 [6633410.001]
  • (PMID = 17167612.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1656785
  •  go-up   go-down


3. Tamer G, Kartal I, Aral F: Pituitary infiltration by non-Hodgkin's lymphoma: a case report. J Med Case Rep; 2009;3:9293

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary infiltration by non-Hodgkin's lymphoma: a case report.
  • INTRODUCTION: Pituitary adenomas represent the most frequently observed type of sellar masses; however, the presence of a rapidly growing sellar tumor, diabetes insipidus, ophthalmoplegia and headaches in an older patient strongly suggests metastasis to the pituitary.
  • Since the anterior pituitary has a great reserve capacity, metastasis to the pituitary and pituitary involvement in lymphoma are usually asymptomatic.
  • As magnetic resonance imaging revealed a sellar mass involving the pituitary gland and infundibular stalk, which also extended into the right cavernous sinus and sphenoid sinus, the patient underwent an immediate transsphenoidal decompression surgery.
  • Histological examination revealed that the mass had been the infiltration of a high grade B-cell non-Hodgkin's lymphoma involving respiratory system epithelial cells.
  • Paranasal sinus computed tomography scanning and magnetic resonance imaging of the thorax and abdomen were performed.
  • Since magnetic resonance imaging did not reveal any abnormality, after paranasal sinus computed tomography was performed, we concluded that the primary lymphoma originated from the sphenoid sinus and infiltrated the pituitary.
  • Chemotherapy and radiotherapy to the sellar area were planned, but the patient died and her family did not permit an autopsy.
  • CONCLUSION: Lymphoma infiltration to the pituitary is difficult to differentiate from pituitary adenoma, meningioma and other sellar lesions.
  • To plan the treatment of lymphoma infiltration of the pituitary gland, it must be differentiated from other sellar lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):574-80 [14764764.001]
  • [Cites] Pituitary. 2005;8(2):139-46 [16379034.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Int J Clin Pract. 1998 Oct;52(7):513-4 [10622097.001]
  • [Cites] Neth J Med. 1987 Apr;30(3-4):135-43 [3600898.001]
  • [Cites] Intern Med. 1994 Dec;33(12):795-8 [7718964.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):155-8 [8145058.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] Haematol Blood Transfus. 1990;33:571-6 [2323657.001]
  • (PMID = 20062782.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803816
  •  go-up   go-down


Advertisement
4. Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, Ribrag V: Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol; 2005 Nov;131(4):468-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
  • Sinonasal lymphoma (SL) is a rare form of extranodal lymphoma.
  • Of 33 SL cases, 14 consecutive diffuse large B-cell lymphomas were treated with CHOP (adriamycin, cyclophosphamide, vincristine and prednisone) or CHOP-like chemotherapy regimen.
  • Eight patients were alive, including seven in CR and six patients had died of their lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Recurrence. Treatment Outcome. Vincristine / administration & dosage


5. Su ZY, Zhang DS, Zhu MQ, Shi YX, Jiang WQ: [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases]. Ai Zheng; 2007 Aug;26(8):919-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
  • BACKGROUND & OBJECTIVE: Primary paranasal sinus lymphoma (PPSL) is a rare presentation of extranodal non-Hodgkin's lymphoma with a natural history distinct from other lymphomas.
  • This study was to evaluate the clinical and pathologic characteristics, treatment outcomes and prognosis of PPSL.
  • RESULTS: The primary involvement sites included the maxillary sinus (11 cases), ethmoid sinus (2 cases), and sphenoid sinus (1 case).
  • The most common type was diffuse large B-cell PPSL (6 cases, 42.9%).
  • All patients received chemotherapy and 6 received radiotherapy after chemotherapy.
  • CONCLUSIONS: PPSL is an uncommon presentation of lymphoma characterized by bulky local disease.
  • Diffuse large B-cell lymphoma is the most common histologic type and the maxillary sinus is the most common original site of PPSL.
  • A combined-modality approach with systemic chemotherapy and local-regional radiation is recommended for PPSL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Maxillary Sinus / surgery. Middle Aged. Neoplasm Staging. Paranasal Sinuses / pathology. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697560.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Proulx GM, Caudra-Garcia I, Ferry J, Harris N, Greco WR, Kaya U, Chan A, Wang CC: Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol; 2003 Feb;26(1):6-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease.
  • The records of 23 patients diagnosed and treated at the Massachusetts General Hospital for extranodal non-Hodgkin's lymphoma of the paranasal sinus and nasal cavity were reviewed.
  • Eight patients had nasal-type NK/T cell and 15 patients had diffuse large B-cell lymphoma (DLBCL).
  • The patients with nasal-type NK/T cell lymphoma predominately involved the nasal cavity (5/8), whereas the DLBCL more often had the paranasal sinuses as the primary site (12/15).
  • All patients received radiation as part of their treatment.
  • Only three patients received chemotherapy as part of their initial treatment for three cycles using a cyclophosphamide, doxorubicin, vincristine, and prednisone-based regimen.
  • A combined-modality approach with local-regional radiation and systemic chemotherapy is recommended for these patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Nasal Cavity. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12576916.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Beginning in May 1985, intrathecal chemotherapy was added to our standard treatment plan of multi-agent chemotherapy and local irradiation.
  • Before 1985, 2 of 5 patients developed leptomeningeal metastasis.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Shohat I, Berkowicz M, Dori S, Horowitz Z, Wolf M, Taicher S, Talmi YP: Primary non-Hodgkin's lymphoma of the sinonasal tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Mar;97(3):328-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the sinonasal tract.
  • OBJECTIVES: We sought to review the records of patients seen at the Chaim Sheba Medical Center (Tel Hashomer, Israel) during a 10-year period with respect to the presenting features, management, and outcome of extranodal non-Hodgkin's lymphoma (NHL) of the sinonasal region.
  • STUDY DESIGN: Eight patients were diagnosed with NHL of the paranasal sinuses from 1993 to 2003.
  • The data were reviewed, and we noted the patient's age, sex, the presenting signs and symptoms, staging, histology, treatment, and outcome of NHL.
  • All cases involved the paranasal sinuses, and the most common symptom was nasal obstruction (6 patients).
  • All the patients had large B-cell lymphoma, and all were treated with combined chemotherapy and radiation.
  • CONCLUSIONS: NHLs of the paranasal sinuses are uncommon.
  • Early diagnosis and combined treatment are essential for achieving an optimal outcome.
  • [MeSH-major] Lymphoma, B-Cell / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024355.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Wang J, Sun NC, Weinstein SM, Canalis R: Primary T-cell-rich B-cell lymphoma of the ethmoid sinus. A case report with 5 years of follow-up. Arch Pathol Lab Med; 2000 Aug;124(8):1213-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell-rich B-cell lymphoma of the ethmoid sinus. A case report with 5 years of follow-up.
  • T-cell-rich B-cell lymphoma (TCRBCL) is an uncommon and recently recognized variant of B-cell non-Hodgkin lymphoma characterized by a few large neoplastic B cells amid a predominant population of reactive T lymphocytes and variable numbers of histiocytes.
  • Accurate diagnosis and proper treatment are essential to assure a favorable prognosis.
  • To our knowledge, this is the first report of ethmoid sinus presentation of TCRBCL in an Epstein-Barr virus-negative 51-year-old man.
  • Combined chemotherapy and radiotherapy were administered based on the correct diagnosis.
  • [MeSH-major] Ethmoid Sinus / pathology. Lymphoma, B-Cell / pathology. Paranasal Sinus Neoplasms / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Biopsy. Combined Modality Therapy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923086.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Yariş N, Kutluk T, Yalçin B, Akyüz C, Büyükpamukçu M: Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis. Pediatr Hematol Oncol; 2000 Jul-Aug;17(5):345-53
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis.
  • Most of the patients with nasal-paranasal and oropharyngeal-nasopharyngeal (NPONP) lymphomas had early-stage disease according to the Murphy system.
  • Treatment results were analyzed to see the effects of the staging in NPONP lymphomas.
  • Fifty-five children (median age 8 years, M/F: 4.5) with NPONP lymphoma were included in this study.
  • The Murphy staging system was used at diagnosis and all cases were restaged according to the TNM system: primary tumor, regional lymph node, and metastasis.
  • The survival rates were analyzed by grouping the patients according to the treatment and stages.
  • Treatment protocols were intensified in most of the early-stage disease treated with modified LSA2-L2 regimen and better survival rates were obtained in these patients.
  • The intensification of the treatment by using intrathecal treatment and doxorubicin in patients with early-stage disease at NPONP location seems effective.
  • It should be revised to predict the prognosis and decision-making for treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nose Neoplasms / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Neoplasm Staging. Oropharyngeal Neoplasms / diagnosis. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Prednisone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):517-20 [11033725.001]
  • (PMID = 10914044.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


11. Hans FJ, Reinges MH, Nolte K, Reipke P, Krings T: Primary lymphoma of the skull base. Neuroradiology; 2005 Jul;47(7):539-42
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the skull base.
  • This case demonstrates the rare finding of a primary malignant lymphoma of the frontobasis and ethmoidal cells in a patient presenting with progressive loss of vision.
  • Computed tomography and MRI demonstrated a homogenously enhancing tumour with extensive bony destructions of the skull base.
  • After transsphenoidal biopsy, histology revealed a highly malignant primary B-cell lymphoma.
  • Tissue diagnosis is, therefore, crucial before a definitive therapy is instituted.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Magnetic Resonance Imaging. Paranasal Sinus Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Drug Therapy. Female. Humans. Immunotherapy. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17(4):567-71 [8331227.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):395-9 [9031122.001]
  • [Cites] Neurosurgery. 1998 Sep;43(3):613-5; discussion 615-6 [9733317.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):50-8; discussion 58-60 [9218295.001]
  • [Cites] Blood. 1995 Oct 15;86(8):2873-5 [7579377.001]
  • [Cites] Surg Neurol. 1996 Sep;46(3):272-8; discussion 278-9 [8781598.001]
  • [Cites] Neurology. 1996 Feb;46(2):435-9 [8614508.001]
  • [Cites] Acta Neurochir (Wien). 2004 May;146(5):533-4 [15118895.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Clin Radiol. 2003 Aug;58(8):621-5 [12887955.001]
  • (PMID = 15940530.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Choussy O, Toussaint B, Dassonville O, Klossek JM, Santini J, Jankowski R: Primary cancer of the sphenoid sinus--a GETTEC study. Head Neck; 2009 Mar;31(3):388-97
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancer of the sphenoid sinus--a GETTEC study.
  • BACKGROUND: Primary involvement of the sphenoid sinus occurs in 2% of all paranasal sinus tumors and is associated with dismal prognosis.
  • METHODS: A total of 23 patients were treated for a primary cancer of the sphenoid sinus from 1988 to 2004.
  • Charts were reviewed for patient-, tumor-, and treatment-related parameters.
  • Pathologic findings included adenoid cystic carcinoma, adenocarcinoma, lymphoma, squamous cell carcinoma, sarcoma, neuroendocrine carcinoma, melanoma, and malignant hemangiopericytoma.
  • Radiotherapy was performed in 18 patients and chemotherapy in 12.
  • Surgery was rarely complete because of advanced stages at presentation, but it yielded better outcomes than other treatments without surgery in non lymphoma-cases.
  • Surgery, including debulking surgery, may be preferred to combined modality treatments without surgery.
  • Highly conformal radiotherapy (adjuvant or definitive) should be encouraged and optimized with concurrent chemotherapy in advanced stages.
  • Aggressive multidisciplinary management including surgery, chemotherapy, and radiotherapy should be encouraged and adapted on histology and tumor extensions.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / therapy. Chemotherapy, Adjuvant. Cranial Nerve Diseases / complications. Diagnostic Imaging. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Middle Aged. Multivariate Analysis. Plasmacytoma / mortality. Plasmacytoma / pathology. Plasmacytoma / therapy. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972425.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


13. Neves MC, Lessa MM, Voegels RL, Butugan O: Primary non-Hodgkin's lymphoma of the frontal sinus: case report and review of the literature. Ear Nose Throat J; 2005 Jan;84(1):47-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the frontal sinus: case report and review of the literature.
  • Non-Hodgkin's lymphoma of the sinonasal tract is an uncommon lesion, representing 1.5 to 15% of all lymphomas.
  • Most cases of primary non-Hodgkin's lymphoma of the sinonasal tract occur in the maxillary sinus, ethmoid sinus, and nasal cavity; its occurrence in the frontal sinus is extremely rare.
  • We report a case of primary type B non-Hodgkin's lymphoma of the frontal sinus in a 43-year-old man.
  • The patient complained of frontal headaches that had not improved with analgesic drugs, and he presented with a frontal bulge that involved the left upper eyelid; the bulge had progressively enlarged over a 3-month period A biopsy of the mass identified the type B non-Hodgkin's lymphoma.
  • Immunohistochemical study not only confirmed the histologic type of the tumor, it also provided some important information about the primary tumor site.
  • Advances in immunohistochemistry have shown that type B non-Hodgkin's lymphoma is more common in North American and European patients, whereas subtype T is more common in Asians and in some Latin Americans.
  • The treatment of this condition is still controversial, but the combination of radiotherapy and chemotherapy has yielded the best results in all stages of the disease.
  • [MeSH-major] Frontal Sinus. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742775.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


14. Hatta C, Ogasawara H, Okita J, Kubota A, Ishida M, Sakagami M: Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification. Auris Nasus Larynx; 2001 Jan;28(1):55-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification.
  • OBJECTIVE: Although the Working Formulation is commonly used to classify NHL in Japan, it has been recognized as imperfect for primary extranodal lymphoma, especially for patients with sinonasal disease because of their histological characteristics.
  • METHODS: Fifty-three patients with non-Hodgkin's malignant lymphoma (NHL) of the sinonasal tract were treated between 1981 and 1997.
  • The primary sites were the nasal cavity (67.8%), maxillary sinus (20.8%), ethmoidal sinus (9.4%), and frontal sinus (1.9%).
  • Based on the origin of the tumor cells, the authors classified NHL of the sinonasal tract into five groups with the REAL classification of Japan: diffuse large B-cell lymphoma (22.6%), peripheral T-cell lymphomas (15.1%), angiocentric lymphoma (35.9%), other lymphomas and unclassified types.
  • Of 53 patients, 39 (73.6%) received chemotherapy and radiotherapy, eight patients received chemotherapy alone, and four patients received radiotherapy alone.
  • The cumulative 5-year survival rates were 28.5% for all of the types, 55.0% for diffuse large B-cell lymphoma, 33.3% for peripheral T-cell lymphoma, and 19.7% for angiocentric lymphoma.
  • Results suggest that conventional combined treatment (CHOP chemotherapy+radiotherapy) is ineffective for NHL of the sinonasal tract, and especially so for NHL in the nasal cavity, NHL with tumor cells with positive T-cell markers, NHL further than Stage IIE and NHL with B symptoms.
  • CONCLUSION:. (1) In light of this ineffectiveness, new therapies must be developed to improve patient outcome instead of the conventional combined treatment;.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / classification. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11137364.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


15. Hon C, Kwok AK, Shek TW, Chim JC, Au WY: Vision-threatening complications of nasal T/NK lymphoma. Am J Ophthalmol; 2002 Sep;134(3):406-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vision-threatening complications of nasal T/NK lymphoma.
  • PURPOSE: Nasal T/NK lineage lymphoma, previously known as lethal midline granuloma, is common among Oriental, Native-American, and Hispanic patients and is invariably associated with Epstein-Barr virus.
  • Ophthalmologic symptoms and signs may precede lymphoma diagnosis or complicate its disease course.
  • METHODS: Records of all lymphoma patients from 1996 to 2000 were retrieved from a computer database, and the primary sites and lineage were reviewed.
  • Nasal T/NK lymphoma was defined by a combination of morphology, positive CD3 epsilon and CD56 expression, in situ hybridization staining for Epstein-Barr virus expressed RNA (EBER), and negative staining for B cell markers (CD20 and CD79a).
  • RESULTS: Thirty-five consecutive patients with T/NK lymphoma were identified.
  • Primary nasal or nasopharyngeal disease was found in 24 patients.
  • The former preceded the diagnosis of lymphoma in two patients and also led to novel ocular complications like rhegmatogenous retinal detachment and macular hole that were successfully managed by ocular surgery.
  • Generally, the prognosis is grave, but remission can still be achieved with aggressive combined chemotherapy and radiotherapy.
  • CONCLUSION: Both oncologists and ophthalmologists should be aware of ocular complications when dealing with known or suspected cases of T/NK lymphoma at diagnosis and relapse.
  • [MeSH-major] Antigens, CD3. Eye Neoplasms / etiology. Granuloma, Lethal Midline / complications. Killer Cells, Natural / pathology. Lymphoma, T-Cell / complications. Paranasal Sinus Neoplasms / complications. Ribosomal Proteins. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12208253.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56; 0 / CD3E protein, human; 0 / RNA-Binding Proteins; 0 / Receptors, Antigen, T-Cell; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


16. Lee JY, Jang YD, Kim HK: The primary role of the otolaryngologist in managing pediatric sinonasal malignancies: an extranodal NK/T-cell lymphoma originating from the inferior turbinate mucosa of the nasal cavity. J Pediatr Hematol Oncol; 2008 May;30(5):401-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The primary role of the otolaryngologist in managing pediatric sinonasal malignancies: an extranodal NK/T-cell lymphoma originating from the inferior turbinate mucosa of the nasal cavity.
  • The primary role of the otolaryngologist in managing patients with a sinonasal malignancy is to make an early diagnosis.
  • Recently, we observed a nasal extranodal natural killer/T-cell lymphoma in a 12-year-old girl with a 6-month history of right nasal obstruction.
  • Her symptom worsened gradually despite medical treatment at a private hospital.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Nasal Mucosa / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Otolaryngology / methods. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458579.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Ma HH, Qian LT, Pan HF, Yang L, Zhang HY, Wang ZH, Ma J, Zhao YF, Gao J, Wu AD: Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol; 2010 Sep;27(3):798-806
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.
  • This study aims to investigate the prognostic factors and long-term treatment outcome in patients with early stage nasal natural killer (NK)/T-cell lymphoma.
  • Early stage (stage IE: 51, stage IIE: 13) nasal NK/T-cell lymphoma (NNTCL) was established according to Ann Arbor staging classification.
  • Results show that the median overall survival (OS) time was 41 months.
  • There is no significant difference between two treatment modalities.
  • Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (PS) score > or = 2, local tumor invasion out of nasal cavity, and lower complete remission (CR) rates in the initial treatment were significant unfavorable independent prognostic factors.
  • PS score before treatment, local tumor invasion out of nasal cavity, and CR rate of the primary treatment may be independent prognostic factors among the subtype lymphoma entity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitoxantrone / administration & dosage. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy. Prednisolone / administration & dosage. Prednisone / administration & dosage. Radioisotope Teletherapy. Radiotherapy, High-Energy. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Cancer. 1996 May 15;77(10):2137-49 [8640683.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1356-69 [10555004.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1274-82 [16923557.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802 [2004957.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Radiother Oncol. 1996 Jan;38(1):1-6 [8850419.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1226-30 [15798768.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):181-9 [16382127.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):599-605 [3417488.001]
  • [Cites] Clin Lab Haematol. 2000 Aug;22(4):215-20 [11012633.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):265-71 [15643509.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):31-8 [17049184.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3785-90 [16109779.001]
  • [Cites] Hematol Oncol. 1992 May-Aug;10(3-4):141-7 [1398510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1511-7 [11075852.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2095-105 [11733360.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1123-6 [11455983.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):261-9 [11730995.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):449-56 [9690537.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • (PMID = 19685292.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP-B protocol; MCOP protocol; VAP-cyclo protocol
  •  go-up   go-down


18. Boussen H, Sethom A, Beddouihech N, Touati S, Gamoudi A, Gritli S, El May A, Ferjaoui M, Benna F, Ladgham A: [Primary sino-nasal lymphomas. Apropos of 25 cases]. Cancer Radiother; 2001 Apr;5(2):150-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary sino-nasal lymphomas. Apropos of 25 cases].
  • PURPOSE: To report on the epidemiological and therapeutic features of a series of Tunisian patients treated for primitive sinonasal lymphoma.
  • PATIENTS AND METHODS: Our retrospective study concerns patients with histologically proven primitive sinonasal lymphoma diagnosed and treated at our institution from 1975 to 1997.
  • Treatment is based on radiotherapy with or without chemotherapy (mainly with the CHOP protocol).
  • DISCUSSION: Radiotherapy remains a standard treatment for sinonasal lymphomas, permitting us to cure localized stages.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Airway Obstruction / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Epistaxis / etiology. Female. Humans. Life Tables. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355579.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


19. Mele L, Ricci P, Nosari A, Tonso A, Fianci L, Cudillo L, Pagano L: Invasive fungal infection in patients with myelodysplastic syndrome: a report of twelve cases. Leuk Lymphoma; 2002 Aug;43(8):1613-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report we analyse the risk factors, clinical characteristics and outcome of patients with myelodysplastic syndrome (MDS) who developed a invasive fungal infection (IFI).
  • The primary localisation of infection was the lung in 10 cases and skin and paranasal sinus in one case each.
  • The factors which appeared related to an unfavourable outcome were intensive chemotherapy within 30 days before IFI diagnosis, presence of multiple localisation at chest X-ray in patients with isolated pulmonary IFI and multiple sites of infection.
  • [MeSH-minor] Adult. Aged. Amphotericin B / therapeutic use. Humans. Male. Middle Aged


20. Mele L, Ricci P, Nosari A, Tonso A, Fianchi L, Cudillo L, Pagano L: Filamentous fungi infection in patients with myelodysplastic syndrome. A report of twelve cases. Leuk Lymphoma; 2002 Jul;43(7):1421-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report we analyse the risk factors, the clinical characteristics and outcome of patients with myelodysplastic syndrome (MDS) who developed an Invasive Fungi Infection (IFI).
  • The primary localization of infection was lung in 10 cases and skin and paranasal sinus in 1 case each.
  • The factors that appeared related to an unfavourable outcome were intensive chemotherapy within 30 days before IFI diagnosis, presence of multiple localization at chest X-ray in patients with isolated pulmonary IFI and multiple sites of infection.
  • [MeSH-minor] Adult. Aged. Amphotericin B / therapeutic use. Data Collection. Female. Follow-Up Studies. Humans. Male. Middle Aged. Opportunistic Infections / etiology. Opportunistic Infections / pathology. Risk Factors. Treatment Outcome


21. Nassenstein K, Wieland R, Schweiger B: Calcifications in untreated Burkitt's lymphoma of the upper jaw. Onkologie; 2005 Apr;28(4):201-3
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifications in untreated Burkitt's lymphoma of the upper jaw.
  • They may occur after chemotherapy or radiotherapy, whereas calcifications in untreated non- Hodgkin's lymphomas are rarely reported in the literature.
  • CASE REPORT: We report the case of a 9-year-old boy who developed tumefaction of the right upper jaw.
  • CT examination revealed a neoplastic lesion in the right upper jaw sinus with destruction of the maxilla and subcutaneous fat infiltration.
  • Histological examination revealed endemic type of Burkitt's lymphoma of the paranasal sinus.
  • CONCLUSION: Our experience showed that calcification can rarely occur also in untreated Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Burkitt Lymphoma / diagnosis. Calcinosis / diagnosis. Calcinosis / etiology. Jaw Neoplasms / complications. Jaw Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840968.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement